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Small-molecule amphiphilic species such as many drug molecules frequen-
tly exhibit low-to-negligible aqueous solubility, and generally have no
identified transport proteins assisting their distribution, yet are able to rapidly
penetrate significant distances into patient tissue and even cross the blood–
brain barrier. Previous work has identified a mechanism of translocation
driven by acid-catalysed lipid hydrolysis of biological membranes, a process
which is catalysed by the presence of cationic amphiphilic drug molecules.
In this study, the interactions of raclopride, a model amphiphilic drug, were
investigated with mixtures of biologically relevant lipids across a range of
compositions, revealing the influence of the chain-melting temperature of
the lipids upon the rate of acyl hydrolysis.1. Introduction
The interplay between the majority of small-molecule compounds and biologi-
cal membranes remains poorly understood, despite intense investment and
research from both academia and industry. Many drugs display poor aqueous
solubility, leading to their absorption by lipid bodies such as cell membranes,
adipose tissue and liposomes in vivo, which may alter the transport kinetics
of the compound, the stability and integrity of the lipid assembly, or both.
These relationships are of critical importance when attempting to understand,
predict or modulate the pharmacokinetics and availability of these compounds.
Hydrophobic and amphiphilic substances such as drug molecules can tra-
verse the bilayer either by simple diffusion or by hijacking the cell’s transport
system [1]. Membrane proteins (including species such as carriers and channels)
mediate substrate flux by facilitated or active transport in the direction of
or against concentration gradients, the latter of which is energy dependent.
Energy is used either in the form of ATP hydrolysis [2], known as primary
active transport, or through the dissipation of electrochemical gradients by coup-
ling transport to secondarymolecules, classified as secondary active transport [3].
In recent years, these proteins have been the focus of clinical attention owing to
their association with multidrug resistance [4].
Unfavourable drug interactions with proteins can have adverse effects, includ-
ing drug resistance and major side effects through low drug specificity. However,
drug–protein interactions are not the only consideration during drug design:
the extent of membrane partitioning of a drug is a key physico-chemical property
that must be considered. The partition coefficient (logP) and distribution function
(logD) of compounds are often used as crude measures of the distribution of
compounds in vivo [5], as Overton’s rule suggests that lipophilic compounds
will traverse a lipid bilayer faster thanmore hydrophilic species [6]. Unfortunately,
while the behaviour of some drug compounds correlates well with log P and logD
values, there are alsomanyexceptions [7], as these parameters in combinationwith
Figure 1. The mechanism of lipid hydrolysis catalysed by the presence of an
amphiphilic species acting as a phase transfer agent, illustrated here with a
phosphatidylcholine species and the CAD raclopride, where R1 and R2 are
alkyl chains. As the reaction progresses, the diacyl species which promote
the formation of lipid bilayers are replaced by highly curved lysolipids and
fatty acids which prefer to form curved interfaces, leading to dramatic
perturbations within the membrane. (Online version in colour.)
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2specific active processes can lead to the sequestration of drugs
within membranes and other non-target tissue. This results in
reduced efficacy in therapeutic uses, leading to increased
doses and subsequent toxicity as well as severely limiting
contrast in applications such as medical imaging.
It is clear that this sequestration of material in non-target
tissues, often referred to as non-specific binding, is a far more
complex process than has been previously thought and that
protein-mediated drug transport alone cannot adequately
describe the translocation of bulky hydrophobic or amphiphilic
molecules not recognized by the cell (e.g. the cationic amphi-
philic drugs; CADs) [8]. In the light of this, other modes of
drug uptake based on direct chemical or physical interactions
between the drug and lipid molecules have been postulated.
Baciu et al. [9] demonstrated the CAD-catalysed hydrolysis
of a phosphatidylcholine membrane via its lipid ester bonds,
generating a molecule of mono-acyl phosphatidylcholine and
the concomitant fatty acid as shown in figure 1. This pro-
cess rapidly causes dramatic perturbations to the membrane
topography, as degradation products begin to accumulate.
Fluorescence microscopy studies have revealed that drug-
bearing membrane fragments are ejected from the membrane
within seconds of the compound’s administration.
Here, we present studies describing lipid hydrolysis by
the dopamine-D2 antagonist raclopride tartrate as a function
of membrane composition. Previous studies have focused
upon model systems comprising pure lipid speciespredominantly in 1,2-dioleoyl-sn-glycero-3-phosphatidyl-
choline (DOPC), as it adopts the fluid lamellar phase over a
wide range of hydrations and temperatures. Model membranes
such as these, comprising a small number of synthetic and pur-
ified lipids, are routinely used to mimic the behaviour of
biological membranes in vitro [10]. These systems are generally
protein free and provide a relatively stable platform with phys-
ical characteristics similar to those found in most cells,
allowing the direct and quantitative analysis of phenomena in
amembrane environment. Although thesemodels are simplistic
compared with biological membranes, they are currently the
only practical option for in vitro characterization of membrane
properties.
To isolate and characterize the influence of the chain
packing within a membrane upon lipid hydrolysis mediated
by raclopride tartrate, saturated and mix-tailed phosphatidyl-
choline lipids were systematically doped into DOPC bilayers,
and the rate(s) of hydrolysis was measured. The structures of
all lipids used are shown in figure 2.
For the first time, to the best of our knowledge, we can
demonstrate direct dependence of the rate of reaction upon
the melting temperature of the lipid, and thus the efficiency
of fatty chain packing interactions within the system.2. Material and methods
Lipids were purchased from Avanti Lipids (AL, USA) at the
highest purity available. All other compounds were purchased
from Sigma–Aldrich (UK), unless otherwise specified and were
of at least 95% purity.
2.1. Lipid preparation
Sample preparation was adapted from previously reported studies
[11]. In each vial, 25 mmol (20 mg) of lipid or lipid mixtures with
5 mol% drug was dissolved in a mixture of 1 : 1 chloroform and
methanol, and the solvent removed under a nitrogen stream. The
lipids or lipid mixtures were then dried under vacuum overnight,
before being hydrated with 60 ml 10 mM phosphate-buffered
saline (PBS) at pH 7.4 to a final concentration of 0.42 M. The assay
vials were then vortexed, and centrifuged three times to ensure
homogeneity and incubated at 378C throughout the course of the
experiments in aluminium heating blocks to prevent the formation
of a thermal gradient in the vials. All buffersweremade using high-
performance liquid chromatography (HPLC)-grade water (VWR,
UK). Samples (6 ml) were taken at 3–4 day intervals, and dispensed
into a 1 ml HPLC sample vial. These samples were dried under
vacuum in a desiccator to halt any further reaction, and were then
redissolved into 1 ml of methanol for HPLC analysis.
2.2. HPLC conditions
Analyses were performed using an all-polyetheretherketone
(PEEK), dual-pump system (model 626 LC, Waters). Measure-
ments were conducted on an experimental 150  3.9 mm Agilent
PLRP-AQ column (packed with 12 mm hydrophilic, hydroxylated
polymer beads with hydrophobic pores of around 100 A˚ and a
pore volume of 45%) and analysed via evaporative light scattering
using an ESA 301 detector. The solvent profile consisted of a short
run at 95% water to clear the buffer and inorganic salts from the
column (which were otherwise found to co-elute with the lyso-
lipids), followed by a rapid climb to 70% methanol and then a
shallow gradient to 95%methanol. Eluting solvents were degassed
through a Degassex DG-401 unit (Phenomenex). Methanol (25 ml)
solution was injected on each occasion using a Waters 771 Plus
autosampler module, giving strong evaporative light-scattering
DOPC
(2 × C18 : 1; –20°C)
DLPC
(2 × C12; 8°C)
DPPC
(2 × C16; 41°C)
C13 PC
(2 × C13; 14°C)
POPC
(C16, C18 : 1; –5°C)
SOPC
(C18, C18 : 1; 6°C)
DMPC
(2 × C14; 22°C)
Figure 2. The structures of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-palmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-tridecanoyl-sn-glycero-
3-phosphatidylcholine (C13 PC) and 1-stearoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (SOPC). Carbon chain lengths and melting transition temperatures given
in parentheses. (Online version in colour.)
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3detector (ELSD) signals with a good signal-to-noise ratio. Cali-
bration was conducted using standard solutions of each lipid in
methanol to give injections of 0.001–0.1 mM. The mass injected
was plotted against the peak area recorded by the ELSD. There
was no significant change in ELSD signal between identical concen-
trations of the different species injected, allowing the hydrolysis
data to be collected as a simple percentage.
2.3. Small-angle X-ray scattering
Small-angle X-ray scattering (SAXS) was conducted using custom-
built equipment, based around a Bede (Durham, UK) Microsource
X-ray generator with integrated optics, an Ealing (Ealing Electro
Optics, UK) linear transition stage and a Photonic Science Ltd
(Battle, UK) Gemstar intensified CCD X-ray detector [12]. X-ray
data were acquired over a 60 s exposure, and spacings were cali-
brated against a silver behenate standard [13]. Sample diffraction
patterns were analysed with the IDL-based AXCESS software pack-
age that was developed by Andrew Heron at Imperial College,
London, UK [9].3. Results and discussion
Prior to probing the effect of raclopride-mediated hydrolysis
of membranes of varying lipid compositions, experiments were
undertaken to analyse the dose–response curve of raclopride
in the standard model membrane system, condensed-phase
DOPC. In line with previously reported studies [9,11],experiments were carried out with 5 mol% raclopride as it pro-
duced a statistically significant, measurable rate of hydrolysis
and no morphological disruption of the host membranes as
measured by SAXS, as shown in figure 3.
To probe the reliability of the condensed-phase results, nine
independently prepared vials containing DOPC and raclo-
pride were assayed and their results compared (figure 4).
Data analysis generated a hydrolysis rate of 0.1308 mol h21
molRAC
21 (p, 11024, r2 ¼ 0.985), and error bars derived
from the standard deviation of the data which were used to
validate all subsequent assays. Lipid hydrolysis was only
observed upon addition of raclopride, confirming that the
drug-catalysed reaction was significantly faster than any
background degradation processes.3.1. Effect of acyl chain saturation on lipid hydrolysis
by raclopride
In order to investigate the effects of saturated lipids within
the fluid membrane with respect to raclopride-mediated
lipid hydrolysis, DOPC bilayers were doped with lipids of
increasing saturated chain lengths. DOPC was chosen as the
host lipid to allow direct comparison of results with previous
studies [9,11], whereas dopant lipids were selected to provide
a congruent set of naturally occurring species, isolating the
contributions of the acyl region to the rates of reaction.
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Figure 3. The small-angle X-ray scatter pattern generated by DOPC contain-
ing 5 mol% raclopride (top); the integral of the pattern monitored over a
period of 500 h. (Online version in colour.)
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Figure 4. The mean data obtained from nine identical assays studying the
hydrolysis of DOPC by raclopride tartrate, prepared and run simultaneously.
The trend-line has equation y ¼ 0.0057x, which is equivalent to a rate of
0.1136 mol h21 molRAC
21; error bars are equal to +2 s.d. of experimental
data. Control values show identical DOPC suspension in the absence of
raclopride tartrate. (Online version in colour.)
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Figure 5. The relationship between saturated-chain lipid concentrations in
the membrane and the rate of its hydrolysis by raclopride tartrate. Remaining
proportion of membrane was composed of DOPC. Error bars are derived from
figure 4 and are smaller than data markers. Shaded region highlights the
region of domain formation in DOPC–DPPC systems, as identified by fluor-
escence methods [15] and X-ray diffraction [16]. (Online version in colour.)
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4These included a range of fully saturated PC lipids:
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyris-
toyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-palmitoyl-
sn-glycerol-3-phosphocholine (DPPC). These lipids contain
fully saturated chains of 12, 14 and 16 carbons, respectively,
and exhibit an increasing gel–fluid transition temperature.
DLPC becomes fully liquid at ca 88C, and DMPC at 22–248C,
whereas pure DPPC melts slightly above 408C [14]. DLPC,
DMPC and DPPC were all mixed with DOPC and prepared as
previously described with 5 mol% raclopride tartrate.Experiments were also conducted using mixtures of
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) with
DOPC. This lipid carries one saturated C16 chain and one
mono-unsaturated C18 chain, and unlike some of the saturated
species [15,16] mixes ideally with DOPC at all ratios, forming a
stable fluid lamellar structure above its chain-melting point of
258C [17]. Under these experimental circumstances, it was
capable of isolating the contribution of the fatty acid tail group
in determining the rate of the reaction with respect to choice of
acyl group and membrane fluidity. Finally, in order to probe
the influence of chain packing efficiency (as typified by themelt-
ing temperature) upon the rates of reaction, the hydrolysis of 1-
stearoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (SOPC) and
the wholly synthetic 1,2-tridecanoyl-sn-glycero-3-phosphatidyl-
choline (C13 PC) were also investigated.
In each of the experiments, lyso-PC was formed at a linear
rate dependent upon the system composition, in a similar
manner to the data in figure 4. The same trends were visible
across the three lipid types (figure 5): hydrolysis in mixtures
containing 20, 40 and 60 mol% saturated lipid was very close
to that observed in pure DOPC. Above this threshold,
hydrolysis began to occur very rapidly and these rates of
hydrolysis appear to increase with increasing acyl chain
length, up to an eightfold increase in the case of DPPC.
The DOPC–POPC system was tested following the same
protocol as described above. Owing to similarities in chemi-
cal structure between the two potential lysolipids coupled
with their propensity to isomerize into the sn-1 form [18],
the DOPC and POPC reaction products co-eluted, thus the
reaction’s chemoselectivity could not be ascertained. How-
ever, these data strongly indicate that raclopride-mediated
hydrolysis is within error the same for DOPC and POPC
lipids, as the observed rates of hydrolysis were independent
of the level of POPC in the bilayers (figure 5).
Absolute rates (0.1136+0.00645 mol h21 molRAC
21)
measured for DOPC/POPC lipid mixtures were identical
under the specified experimental conditions; SAXS data
(not shown) confirmed that no bulk mesophase changes
were detected during the experimental period.
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Figure 6. The correlation between a phosphatidylcholine lipid’s rate of
hydrolysis by 5 mol% raclopride tartrate and its chain-melting temperature,
after incubation at 378C with 3 : 1 PBS w/w. The line of fit is equal to y ¼
0.0141x2 3.510, added as a guide for the eye; errors are calculated from
figure 4 and are smaller than data markers. (Online version in colour.)
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5While the hydrolysis data presented in figure 5 also indicate
a trend of increase in rate with acyl chain length, there is an
obvious and significant discontinuity between the rates of
formation of lysolipid species in mixtures dominated by un-
saturated lipids relative to those comprising mostly saturated
species. Temperature- and composition-dependent phase coex-
istence regions have been observed between ordered domains
enriched in saturated lipids, and fluid-disordered regions
enriched in unsaturated molecules. In the case of DOPC–
DPPC mixtures at 378C, the coexistence region has been
found by fluorescence methods [15] and X-ray diffraction [16]
to form just below 80 mol% DPPC, which agrees well with
the experimental data presented above. Although this effect
has not been observed in the more fluid DLPC and DMPC sys-
tems, the imperfect mixing between the lipid species and the
wide disparity between their chain-melting temperatures
suggests that something more dynamic and short-lived, but
similar, may occur in these shorter chain species.
A striking observation that can be made from the data
above is the strong, positive correlation between the melting
transition temperature of the lipids and the rate at which they
are consumed by raclopride-mediated hydrolysis. Further-
more, this trend shows no discontinuity across the Lb! La
phase transition. To strengthen the confidence in this associ-
ation, hydrolysis experiments were undertaken using 5 mol%
raclopride in two further lipids with chain-melting transition
temperatures intermediate between those already establi-
shed. These were SOPC and C13 PC, described previously
in figure 2, with melting temperatures of 68C and 148C,
respectively. The data generated in these experiments fitted
the trend closely, as shown in figure 6.
3.2. Potential mechanisms
These experimental findings indicate that the hydrolysis of
phosphatidylcholine lipids by raclopride is proportional to
the chain-melting temperature of the lipid aggregate. The
explanations for the observed effects cannot at this stage be
conclusively identified: the chain-melting temperature is a
complex phenomenon, related to the physical and electronic
shapes of the component lipids, the viscosity of themembrane,its surface topology and a numberof other factors. A number of
hypotheses present themselves, some of which are outlined
below; experiments are ongoing to determine which of these
predominate in both laboratory and biological conditions.
The introduction of the saturated lipid species, with their
relatively high transition temperatures, causes phase separation
and eventual bulk phase changes to the system and have a
number of implications. It has been demonstrated that amphi-
philic compounds experience a log P lower by an order of
magnitude or more when lipids are in the gel phase compared
with the fluid lamellar (although this depends to some degree
on the structure of the dopant) [19]. This suggests that while
logPmust contribute to the overall rate, as somedegree ofmem-
brane penetration is prerequisite for the reaction to occur, it
is not the sole rate-determining factor in the reaction as
gel-phase systems reacted significantly faster than those in La.
There is also evidence that shorter-chained lipids are better
at sequestering small amphiphilic molecules than longer lipids
when both are in the fluid phase [20], presumably because of
the greater free volume between chains creating more space for
the incorporation of dopant molecules. It has been demon-
strated that the addition of fatty acids to such membranes
will decrease the transition temperature under all pH con-
ditions below their pKa in the membrane (around 7.7) [21]
by intercalating between lipid molecules (thus affecting inter-
head-group interactions) [22] and introducing anionic charge
to the interface. This, in turn, will change the partition function
and membrane topography experienced by any amphiphile
such as raclopride.
However, the regiochemistry of the system is also impor-
tant. If the rate-determining step of the hydrolysis reaction is
the protonation of the lipids’ ester groups, then the two species
must necessarily be in close proximity for the process to occur.
It is hypothesized that a dominant factor determining the rate
of lipid hydrolysis in these systems is linked to the depthwithin
the membrane at which the CAD resides, and that this is deter-
mined largely by the size and population of free volume voids
within the hydrophobic core of the membrane.
The strength of the interchain forces controls the formation
or otherwise of voids, packing defects within the hydrophobic
core of the membrane [23], and it is suggested that these control
the depth towhich raclopride partitions into the membrane. For
the reaction to progress, the free proton carried by theCADmust
be in close proximity to the estermoieties of the lipidmembrane:
here, we propose that these voids promote the migration of the
CAD towards the hydrophobic centre of the membrane, into a
region where they are effectively sequestered and passivated.
The lackof change in the SAXS images to the administration
of raclopride was confirmed via fluorescence experiments with
the surface charge density probe N-(fluorescein-5-carbonyl)-
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine FPE [24] (not
shown), which showed that despite the hydrolytic effects of
the drug at a molecular level it had limited structural effect
upon the membrane in the head-group region, demonstrating
that the electronic and steric influence of the drugwasminimal.
This suggests that raclopride forms either an non-ionized,
hydrophobic species or some form of net-neutral zwitterion
or internal salt species [25], making its incorporation into the
membrane interior much more favourable if the space is avail-
able to accommodate it.
In this model, raclopride acts more like a phase transfer
agent, forming only transiently charged species which reside
predominantly below thewater interface. Themore disordered
rsif.royalsocietypublishing.org
6and fluid the membrane, the greater the free volume available
to sequester the drug molecules in the membrane core, where
they are unable to either acquire protons or deliver them to
the lipids’ acyl regions. It has not been possible to definitively
identify this mechanism as that underpinning the observed
phenomena and indeed it may be the case that they result
from a complex combination of these and other effects: how-
ever, the combination of drug sequestration into lipid void
volumes and a transiently cationic drug present a plausible
hypothesis around which further studies will be based.J.R.Soc.Interface
11:201310624. Conclusion
The above study demonstrates that small changes in compo-
sition between biological membranes may have dramatic
effects upon the behaviour of an amphiphile with its constitu-
ent lipids. If this behaviour plays a significant role in
determining the systemic transport of such species, as postu-
lated by Baciu et al. [9], such differences could determine a
compound’s success and failure in clinical trials. The identifi-
cation of a consistent, reproducible and linear relationship
between the composition and rate of digestion of a membrane
also provides, for the first time, a testable explanation for the
structural effects some drug molecules have been observed
to exert upon their surrounding tissue upon prolonged admin-
istration. A number of CAD species cause lipid storage
disorders such as phospholipidosis within cells [26]: it may
be that this and related conditions are as much a function of
the drugs’ direct interactions with the membranes’ lipidmatrix as it is with any family of proteins. These interactions
might be directly probed in vitro using cell cultures incubated
in media of differing lipid content; any differences in mem-
brane morphology between cultures can then be attributed
to the differences between those membrane compositions
rather than any other factor, although it may not be possible
to generate quantitative information in the manner of this
study from such experiments.
The complexity of the trends described in this study high-
lights some of the difficulties in modelling or attempting to
predict the behaviour of the diverse and highly dynamic
environment of biological membranes. By studying these reac-
tions in condensed phase systems where reaction rates are
considerably slower than fluorescence-based studies in giant
vesicles [9], it is possible to quantify the rates with respect to sys-
tematic changes in bilayer composition on sufficiently large
populations to produce statistically relevant data. These exper-
iments provide an effective method to probe and quantify
drug–lipid interactions, thus characterizing fromachemical per-
spective a reaction which can be applied to more complex
biological systems. They also highlight the importance of prob-
ing drug–lipid interactions and the role these interactions have
in drug administration and systemic transport.
Data accessibility. All lysolipid concentration measurements are available
via Figshare [27].
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